Panna Sharma is the President, Chief Executive Officer, and a Board Member of Lantern Pharma Inc., an oncology-focused clinical stage pharmaceutical company.

His work is particularly focused on oncology, drug development, and the application of artificial intelligence and machine learning to address some of the most pressing challenges in personalized medicine. By leveraging advanced computational approaches, he has contributed to efforts aimed at reducing the risk, cost, and development timelines associated with bringing innovative therapies and diagnostics to patients.

He is an accomplished biotechnology and life sciences leader with extensive experience guiding public and private companies through periods of growth, transformation, and innovation. Throughout his career, he has helped organizations scale through a combination of organic growth strategies, internal alignment, capital raising, strategic partnerships, and corporate transactions.

His expertise spans biotechnology, life sciences, diagnostics, environmental sciences, biopharmaceutical services, healthcare data, and artificial intelligence. He also has significant experience with public companies, corporate turnarounds, precision medicine, next-generation sequencing, and the commercialization of emerging technologies.

With a strong interdisciplinary perspective, he is committed to advancing data-driven innovation and translating scientific discoveries into scalable solutions that improve healthcare outcomes and accelerate the future of precision medicine.